![]() ![]() Of these patients, 5 underwent subsequent MRI and 1 had a repeat 68Ga-DOTATATE PET/CT to further characterize new lesions seen. In patients who had prior imaging available for comparison, there were new lesions identified on 68Ga-DOTATATE PET/CT in 21 patients (33.3%) that were not identified on other prior imaging modalities. The primary sites of disease from the most to the least common were the pancreas (36.5%), small bowel (22.2%), unknown primary (15.9%), lung (6.3%), large bowel (6.3%), and mesentery (4.8%), and other locations accounted for 7.9%. The most common primary diagnosis was undifferentiated NET (63.5%), followed by carcinoid (27.0%), paraganglioma (4.8%), insulinoma (3.2%), and pheochromocytoma (1.6%). Six patients had 2 or more 68Ga-DOTATATE PET/CT examinations. The estimated incidence of NETs for the combined populations of the United States and the European Union is approximately 47,300 patients per year.A total of 81 68Ga-DOTATATE PET/CT scans in 74 patients were found, and 11 patients were excluded from analysis as they had no prior imaging available for comparison, with resultant analysis cohort of 63 patients. NETs have receptors for somatostatin, a hormone that regulates the endocrine system. These cells are found throughout the body in distinct organs, such as the stomach, intestines, pancreas, lungs, and other locations. NETs are rare benign or malignant tumors that develop in the hormone-producing cells of the body’s neuroendocrine system. We believe that the use of Netspot should also offer increased comfort for patients by potentially shortening a procedure that is currently performed over 24 hours or more to just a few hours.” ![]() “NETSPOT has the potential to significantly improve the accuracy of NET diagnosis, while reducing radiation exposure for patients. “The FDA approval of Netspot is a key milestone in our mission of improving the lives of NET patients,” said Stefano Buono, CEO of AAA. This information is important for planning the appropriate course of therapy.” “Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor. Food and Drug Administration (FDA, Silver Spring, MD, USA) Center for Drug Evaluation and Research (CDER). “Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical,” said Libero Marzella, MD, PhD, director of the division of medical imaging products at the U.S. As Netspot contributes to the overall long-term cumulative radiation exposure, patients should drink and urinate as often as possible during the first hours following administration to help reduce risk. The imaging agent functions as an analogue of somatostatin, with uptake of the dotatate reflecting levels of somatostatin receptor density in NETs. Netspot, a product of Advanced Accelerator Applications (AAA Saint-Genis-Pouilly, France), is a sterile, single-dose kit for the preparation of Ga 68 dotatate injection, a radioactive diagnostic agent used in positron emission tomography (PET) imaging. A novel radioactive probe will help locate tumors in adult and pediatric patients suffering from somatostatin receptor positive neuroendocrine tumors (NETs). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |